proxyvotesnow.com

Home › Companies › OCULAR THERAPEUTIX INC. › 2024-2025

OCULAR THERAPEUTIX INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and OCULAR THERAPEUTIX INC.’s Form 8-K, filed 2025-06-11 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 8Ballot items
  • 185Asset managers
  • 1,231Fund votes
  • 2025-06-11Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore OCULAR THERAPEUTIX INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by OCULAR THERAPEUTIX INC.

These tallies are OCULAR THERAPEUTIX INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-11 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

OCULAR THERAPEUTIX INC. — official shareholder meeting results, meeting held 2025-06-11
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Seung Suh Hong, Ph.D. 100,220,435---- 11,003,21031,460,400 Majority: yes
Elect Director: Richard L. Lindstrom, M.D. 89,771,755---- 21,451,89031,460,400 Majority: yes
Elect Director: Leslie J. Williams 101,077,347---- 10,146,29831,460,400 Majority: yes
(2) The Company's stockholders approved a non-binding, advisory proposal regarding the compensation of the Company's named executive officers. 83,186,51627,851,866185,263 --31,460,400 Majority: yes
(3) The Company's stockholders approved Amendment No. 4 to increase the number of shares of common stock of the Company issuable under the 2021 Stock Incentive Plan by 8,750,000 shares. 88,785,38922,350,44487,812 --31,460,400 Majority: yes
(4) The Company's stockholders approved the Amended and Restated 2014 Employee Stock Purchase Plan to increase the number of shares of common stock of the Company issuable thereunder by 2,000,000 shares and to remove the annual "evergreen" 107,048,8334,117,63557,177 --31,460,400 Majority: yes
(5) The Company's stockholders approved the proposal to amend the Company's Restated Certificate of Incorporation, as amended, to provide for officer exculpation. 105,375,3475,774,80173,497 --31,460,400 Majority: yes
(6) The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025. 139,215,3853,425,80442,856 ---- Majority: yes

Source: OCULAR THERAPEUTIX INC., Form 8-K, filed with the SEC on 2025-06-11 — read the filing on EDGAR.

How asset managers voted at the OCULAR THERAPEUTIX INC. 2024-2025 meeting

Each item below shows how the 185 asset managers that disclosed a OCULAR THERAPEUTIX INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To approve an advisory vote on named executive officer compensation.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 10 wordings of this item as funds reported it.

75% Majority: yes · of votes cast

FOR 75%AGAINST 25%
FOR: 83,186,516AGAINST: 27,851,866

OCULAR THERAPEUTIX INC.’s own tally for this item (“(2) The Company's stockholders approved a non-binding, advisory proposal regarding the compensation of the Company's named executive officers.”): 83,186,516 for, 27,851,866 against, per its Form 8-K filed 2025-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 159,262,024 outstanding shares: 52.2% for, 17% against (70% of the company cast a for/against vote).

The 184 asset managers below cast 72% of the shares they voted on this item FOR (74,550,371 for, 28,620,555 against).

FOR 72%AGAINST 28%
FOR: 74,550,371 (72.2%)AGAINST: 28,620,555 (27.7%)ABSTAIN: 15,762 (0.0%)
Largest asset managers voting on “To approve an advisory vote on named executive officer compensation.” at OCULAR THERAPEUTIX INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Deep Track Capital, LP14,217,4420 00For
VR Adviser, LLC12,762,4620 00For
BlackRock218,7108,412,407 00Against
Fidelity8,471,06541,278 00For
Vanguard8,447,9982,959 00For
Avoro Capital Advisors LLC7,743,9270 00For
TCG Crossover Management, LLC5,319,1480 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.04,565,670 00Against
GEODE CAPITAL MANAGEMENT, LLC3,384,9310 00For
DELTEC ASSET MANAGEMENT LLC2,662,2780 00For
Logos Global Management LP02,446,328 00Against
Octagon Capital Advisors LP2,377,5880 00For
Charles Schwab02,247,994 00Against
Citadel2,089,3820 00For
State Street1,932,96940,160 00For
Artisan01,664,623 00Against
Opaleye Management Inc.1,595,0000 00For
FRANKLIN ADVISERS INC01,170,047 00Against
Paradigm Biocapital Advisors LP0909,492 00Against
Northern Trust811,1809,310 00For
Allspring0788,674 00Against
Invesco0723,659 00Against
Point720720,384 00Against
AXA INVESTMENT MANAGERS UK Ltd0559,519 00Against
Nuveen414,1040 00For

Showing the 25 largest of 184 asset managers. See all 184 in the interactive database.

2. To approve an amendment to the Ocular Therapeutix, Inc. 2021 Stock Incentive Plan, as amended, to increase the number of shares of common stock issuable thereunder by 8,750,000 shares.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%AGAINST 20%
FOR: 88,785,389AGAINST: 22,350,444

OCULAR THERAPEUTIX INC.’s own tally for this item (“(3) The Company's stockholders approved Amendment No. 4 to increase the number of shares of common stock of the Company issuable under the 2021 Stock Incentive Plan by 8,750,000 shares.”): 88,785,389 for, 22,350,444 against, per its Form 8-K filed 2025-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 159,262,024 outstanding shares: 56% for, 14% against (70% of the company cast a for/against vote).

The 50 asset managers below cast 76% of the shares they voted on this item FOR (18,025,081 for, 5,573,910 against).

FOR 76%AGAINST 24%
FOR: 18,025,081 (76.3%)AGAINST: 5,573,910 (23.6%)ABSTAIN: 15,762 (0.1%)
Largest asset managers voting on “To approve an amendment to the Ocular Therapeutix, Inc. 2021 Stock Incentive Plan, as amended, to increase the” at OCULAR THERAPEUTIX INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,105,9700 00For
Fidelity3,094,0712,221,374 00For
BlackRock4,680,2690 00For
Charles Schwab01,123,870 00Against
Artisan0806,654 00Against
FRANKLIN STRATEGIC SERIES0410,100 00Against
TIAA406,5400 00For
Allspring0394,337 00Against
Saturn V Capital Management LP328,0490 00For
Equitable319,5700 00For
OPTIMUM FUND TRUST244,9840 00For
QUANTITATIVE MASTER SERIES LLC185,6710 00For
Invesco166,8620 00For
Empower126,2390 00For
Lincoln Financial117,0000 00For
Global X093,050 00Against
1290 Funds083,657 00Against
AIG/SunAmerica080,769 00Against
Northern Trust73,8750 00For
John Hancock055,201 00Against
ProShares049,954 00Against
Pacific Life49,1200 00For
Nationwide41,8553,498 00For
Voya042,611 00Against
T. Rowe Price037,770 00Against

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

3. To approve an amendment and restatement of the Ocular Therapeutix, Inc. 2014 Employee Stock Purchase Plan to increase the number of shares of common stock issuable thereunder by 2,000,000 shares and to remove the annual "evergreen" provision.

COMPENSATIONMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 107,048,833AGAINST: 4,117,635

OCULAR THERAPEUTIX INC.’s own tally for this item (“(4) The Company's stockholders approved the Amended and Restated 2014 Employee Stock Purchase Plan to increase the number of shares of common stock of the Company issuable thereunder by 2,000,000 shares and to remove the”): 107,048,833 for, 4,117,635 against, per its Form 8-K filed 2025-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 159,262,024 outstanding shares: 67% for, 3% against (70% of the company cast a for/against vote).

The 49 asset managers below cast 99.9% of the shares they voted on this item FOR (23,597,970 for, 15,762 against).

FOR 99.9%
FOR: 23,597,970 (99.9%)AGAINST: 15,762 (0.1%)
Largest asset managers voting on “To approve an amendment and restatement of the Ocular Therapeutix, Inc. 2014 Employee Stock Purchase Plan to i” at OCULAR THERAPEUTIX INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,105,9700 00For
Fidelity5,315,4450 00For
BlackRock4,680,2690 00For
Charles Schwab1,123,8700 00For
Artisan806,6540 00For
FRANKLIN STRATEGIC SERIES410,1000 00For
TIAA406,5400 00For
Allspring394,3370 00For
Saturn V Capital Management LP328,0490 00For
Equitable319,5700 00For
OPTIMUM FUND TRUST244,9840 00For
QUANTITATIVE MASTER SERIES LLC185,6710 00For
Invesco166,8620 00For
Empower126,2390 00For
Lincoln Financial117,0000 00For
Global X93,0500 00For
1290 Funds83,6570 00For
AIG/SunAmerica80,7690 00For
Northern Trust73,8750 00For
John Hancock55,2010 00For
ProShares49,9540 00For
Pacific Life49,1200 00For
Nationwide45,3530 00For
Voya42,6110 00For
T. Rowe Price37,7700 00For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

4. TO APPROVE AN AMENDMENT OF OUR RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, TO PROVIDE FOR OFFICER EXCULPATION.

OTHERMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 105,375,347AGAINST: 5,774,801

OCULAR THERAPEUTIX INC.’s own tally for this item (“(5) The Company's stockholders approved the proposal to amend the Company's Restated Certificate of Incorporation, as amended, to provide for officer exculpation.”): 105,375,347 for, 5,774,801 against, per its Form 8-K filed 2025-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 159,262,024 outstanding shares: 66% for, 4% against (70% of the company cast a for/against vote).

The 48 asset managers below cast 98% of the shares they voted on this item FOR (22,709,197 for, 560,724 against).

FOR 98%
FOR: 22,709,197 (97.5%)AGAINST: 560,724 (2.4%)ABSTAIN: 15,762 (0.1%)
Largest asset managers voting on “TO APPROVE AN AMENDMENT OF OUR RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, TO PROVIDE FOR OFFICER EXCUL” at OCULAR THERAPEUTIX INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,105,9700 00For
Fidelity5,315,4450 00For
BlackRock4,680,2690 00For
Charles Schwab1,123,8700 00For
Artisan806,6540 00For
FRANKLIN STRATEGIC SERIES0410,100 00Against
TIAA406,5400 00For
Allspring394,3370 00For
Equitable319,5700 00For
OPTIMUM FUND TRUST244,9840 00For
QUANTITATIVE MASTER SERIES LLC185,6710 00For
Invesco166,8620 00For
Empower126,2390 00For
Lincoln Financial117,0000 00For
Global X093,050 00Against
1290 Funds83,6570 00For
AIG/SunAmerica80,7690 00For
Northern Trust73,8750 00For
John Hancock55,2010 00For
ProShares49,9540 00For
Pacific Life49,1200 00For
Nationwide41,8553,498 00For
Voya42,6110 00For
T. Rowe Price37,7700 00For
New York Life033,393 00Against

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.

5. To ratify the appointment of PricewaterhouseCoopers LLP as Ocular Therapeutix's independent registered public accounting firm for the fiscal year ending December 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 139,215,385AGAINST: 3,425,804

OCULAR THERAPEUTIX INC.’s own tally for this item (“(6) The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025.”): 139,215,385 for, 3,425,804 against, per its Form 8-K filed 2025-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 159,262,024 outstanding shares: 87% for, 2% against (90% of the company cast a for/against vote).

The 48 asset managers below cast 99.9% of the shares they voted on this item FOR (23,268,361 for, 1,560 against).

FOR 99.9%
FOR: 23,268,361 (99.9%)AGAINST: 1,560 (0.0%)ABSTAIN: 15,762 (0.1%)
Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP as Ocular Therapeutix's independent registered public ” at OCULAR THERAPEUTIX INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,105,9700 00For
Fidelity5,315,4450 00For
BlackRock4,680,2690 00For
Charles Schwab1,123,8700 00For
Artisan806,6540 00For
FRANKLIN STRATEGIC SERIES410,1000 00For
TIAA406,5400 00For
Allspring394,3370 00For
Equitable319,5700 00For
OPTIMUM FUND TRUST244,9840 00For
QUANTITATIVE MASTER SERIES LLC185,6710 00For
Invesco166,8620 00For
Empower126,2390 00For
Lincoln Financial117,0000 00For
Global X93,0500 00For
1290 Funds83,6570 00For
AIG/SunAmerica80,7690 00For
Northern Trust73,8750 00For
John Hancock55,2010 00For
ProShares49,9540 00For
Pacific Life49,1200 00For
Nationwide45,3530 00For
Voya42,6110 00For
T. Rowe Price37,7700 00For
New York Life33,3930 00For

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.

6. To elect three Class II directors, each to serve until the 2028 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Leslie J. Williams

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%
FOR: 101,077,347WITHHELD: 10,146,298

OCULAR THERAPEUTIX INC.’s own tally for this item (“Elect Director: Leslie J. Williams”): 101,077,347 for, 10,146,298 withheld, per its Form 8-K filed 2025-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 159,262,024 outstanding shares: 63% for, 6% withheld (70% of the company cast a for/withheld vote).

The 47 asset managers below cast 100% of the shares they voted on this item FOR (17,956,526 for, 0 against).

FOR 77%ABSTAIN 23%
FOR: 17,956,526 (77.1%)ABSTAIN: 5,329,057 (22.9%)
Largest asset managers voting on “To elect three Class II directors, each to serve until the 2028 Annual Meeting of Stockholders and until his o” at OCULAR THERAPEUTIX INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,105,9700 00For
Fidelity5,274,1670 41,2780For
BlackRock52,1080 4,628,1610Abstain
Charles Schwab1,123,8700 00For
Artisan806,6540 00For
FRANKLIN STRATEGIC SERIES410,1000 00For
TIAA406,5400 00For
Allspring394,3370 00For
Equitable00 319,5700Abstain
OPTIMUM FUND TRUST244,9840 00For
QUANTITATIVE MASTER SERIES LLC00 185,6710Abstain
Invesco166,8620 00For
Empower126,2390 00For
Lincoln Financial117,0000 00For
Global X93,0500 00For
1290 Funds83,6570 00For
AIG/SunAmerica80,7690 00For
Northern Trust73,8750 00For
John Hancock55,2010 00For
ProShares49,9540 00For
Pacific Life00 49,1200Abstain
Nationwide3,4980 41,8550Abstain
Voya42,6110 00For
T. Rowe Price37,7700 00For
New York Life33,3930 00For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

7. To elect three Class II directors, each to serve until the 2028 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Richard L. Lindstrom, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD 19%
FOR: 89,771,755WITHHELD: 21,451,890

OCULAR THERAPEUTIX INC.’s own tally for this item (“Elect Director: Richard L. Lindstrom, M.D.”): 89,771,755 for, 21,451,890 withheld, per its Form 8-K filed 2025-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 159,262,024 outstanding shares: 56% for, 13% withheld (70% of the company cast a for/withheld vote).

The 47 asset managers below cast 100% of the shares they voted on this item FOR (16,929,679 for, 0 against).

FOR 73%ABSTAIN 27%
FOR: 16,929,679 (72.7%)ABSTAIN: 6,355,904 (27.3%)
Largest asset managers voting on “To elect three Class II directors, each to serve until the 2028 Annual Meeting of Stockholders and until his o” at OCULAR THERAPEUTIX INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,105,9700 00For
Fidelity5,274,1670 41,2780For
BlackRock52,1080 4,628,1610Abstain
Charles Schwab1,123,8700 00For
Artisan806,6540 00For
FRANKLIN STRATEGIC SERIES410,1000 00For
TIAA406,5400 00For
Allspring00 394,3370Abstain
Equitable00 319,5700Abstain
OPTIMUM FUND TRUST244,9840 00For
QUANTITATIVE MASTER SERIES LLC00 185,6710Abstain
Invesco00 166,8620Abstain
Empower126,2390 00For
Lincoln Financial117,0000 00For
Global X93,0500 00For
1290 Funds00 83,6570Abstain
AIG/SunAmerica00 80,7690Abstain
Northern Trust00 73,8750Abstain
John Hancock00 55,2010Abstain
ProShares00 49,9540Abstain
Pacific Life00 49,1200Abstain
Nationwide3,4980 41,8550Abstain
Voya00 42,6110Abstain
T. Rowe Price37,7700 00For
New York Life33,3930 00For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

8. To elect three Class II directors, each to serve until the 2028 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Seung Suh Hong, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%
FOR: 100,220,435WITHHELD: 11,003,210

OCULAR THERAPEUTIX INC.’s own tally for this item (“Elect Director: Seung Suh Hong, Ph.D.”): 100,220,435 for, 11,003,210 withheld, per its Form 8-K filed 2025-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 159,262,024 outstanding shares: 63% for, 7% withheld (70% of the company cast a for/withheld vote).

The 47 asset managers below cast 100% of the shares they voted on this item FOR (22,348,257 for, 0 against).

FOR 96%
FOR: 22,348,257 (96.0%)ABSTAIN: 937,326 (4.0%)
Largest asset managers voting on “To elect three Class II directors, each to serve until the 2028 Annual Meeting of Stockholders and until his o” at OCULAR THERAPEUTIX INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,105,9700 00For
Fidelity5,315,4450 00For
BlackRock4,680,2690 00For
Charles Schwab1,123,8700 00For
Artisan806,6540 00For
FRANKLIN STRATEGIC SERIES410,1000 00For
TIAA406,5400 00For
Allspring00 394,3370Abstain
Equitable156,7500 162,8200Abstain
OPTIMUM FUND TRUST244,9840 00For
QUANTITATIVE MASTER SERIES LLC185,6710 00For
Invesco166,8620 00For
Empower126,2390 00For
Lincoln Financial117,0000 00For
Global X93,0500 00For
1290 Funds00 83,6570Abstain
AIG/SunAmerica00 80,7690Abstain
Northern Trust73,8750 00For
John Hancock00 55,2010Abstain
ProShares00 49,9540Abstain
Pacific Life49,1200 00For
Nationwide45,3530 00For
Voya42,6110 00For
T. Rowe Price37,7700 00For
New York Life33,3930 00For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Largest OCULAR THERAPEUTIX INC. shareholders voting in 2024-2025

Ranked by the number of OCULAR THERAPEUTIX INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 159,262,024 shares outstanding at the time of that meeting.

Top OCULAR THERAPEUTIX INC. shareholders by shares voted, 2024-2025
#Asset manager % of shares outstanding
1Deep Track Capital, LP 8.93%
2VR Adviser, LLC 8.01%
3BlackRock 5.42%
4Fidelity 5.34%
5Vanguard 5.31%
6Avoro Capital Advisors LLC 4.86%
7TCG Crossover Management, LLC 3.34%
8ADAGE CAPITAL PARTNERS GP, L.L.C. 2.87%
9GEODE CAPITAL MANAGEMENT, LLC 2.13%
10DELTEC ASSET MANAGEMENT LLC 1.67%

Reported OCULAR THERAPEUTIX INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

OCULAR THERAPEUTIX INC. beneficial owners on record for the 2024-2025 proxy season
Holder % outstanding Disclosure
FMR LLC 19.96% 13G
Deep Track Capital, LP 13.09% 13G
SUMMER ROAD LLC 7.62% 13G
BlackRock 7.54% 13F
Vanguard Group 5.25% 13F
Citadel Advisors 3.15% 13F
Opaleye Management Inc. 2.73% 13G
Geode Capital 2.15% 13F
State Street 2.13% 13F
Morgan Stanley 1.37% 13F

Percentages above are of 159,262,024 shares outstanding, as reported by OCULAR THERAPEUTIX INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from OCULAR THERAPEUTIX INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At OCULAR THERAPEUTIX INC.'s shareholder meeting held 2025-06-11, in the 2024-2025 proxy season, 185 asset managers reported how they voted on 8 ballot items in their SEC Form N-PX filings, covering 1,231 separate fund positions. On the most widely held item on that ballot — To approve an advisory vote on named executive officer compensation. — FOR was 75% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: OCULAR THERAPEUTIX INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-11.

OCULAR THERAPEUTIX INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.